Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...
19h
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.
Professor Nancy Ip discusses her groundbreaking neuroscience research, focusing on neurotrophic factors and innovative ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reduced by 425,744 shares, marking a 63.01% reduction and a -0.96% impact on the ...
The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...
THE DEPARTMENT of STEM Education in Mary Immaculate College (MIC) has collaborated with the University of Limerick (UL), and ...
Alvotech (NASDAQ: ALVO, or the "Company”), a global biotech company specializing in the development and manufacture of ...
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback